Managing Cholestatic Pruritus in PBC

Key Takeaways:

• Pruritus affects roughly 2 of 3 patients with primary biliary cholangitis (PBC) over the disease course, fluctuates over time, and does not correlate with disease stage or biochemical severity – so it must be elicited directly at every visit.
• Management is stepwise and class-based: bile acid sequestrants, then rifampin, opioid antagonists, and sertraline. The ileal bile acid transporter (IBAT) inhibitor class is now FDA-approved, with linerixibat approved in 2026 specifically for cholestatic pruritus in PBC.
• Disease-modifying choice also shapes itch: peroxisome proliferator-activated receptor (PPAR) agonists range from neutral (elafibranor) to itch-reducing (seladelpar), and bezafibrate improves pruritus, making proactive assessment central to therapy selection.

Pruritus is one of the most burdensome symptoms of primary biliary cholangitis (PBC), affecting roughly 2 of 3 patients over the disease course, with persistent itch in about a third and severe intensity in more than 1 in 10.¹

It can precede diagnosis, fluctuate unpredictably, and – importantly – arise at any disease stage independent of cholestasis severity. Because itch intensity does not track with laboratory markers, and because patients often do not connect it to their liver disease, pruritus must be elicited directly rather than assumed to mirror biochemistry.^1,2

Pruritogens driving the itch

The pathophysiology is multifactorial and only partially understood. Cholephilic pruritogens accumulating in the enterohepatic circulation are central – certain bile acid subspecies activate MRGPRX4 on sensory neurons, and removing these compounds reliably improves itch.¹

Autotaxin and its product lysophosphatidic acid (LPA) are elevated in cholestatic pruritus, and systemic autotaxin activity correlates with itch intensity and falls with successful treatment. Endogenous opioid and serotonin signaling contribute as well, providing the rationale for several rungs of the treatment ladder.^1,2

The symptom-directed ladder

Ursodeoxycholic acid (UDCA) remains first-line for PBC but does not relieve pruritus, so symptom-directed therapy is layered on top. Guideline-recommended first-line antipruritic therapy is the bile acid sequestrant cholestyramine, the only labeled agent for cholestatic pruritus; dosing must be separated from UDCA and other drugs by several hours to avoid binding interactions.^1-3

When sequestrants are insufficient, rifampin is the established next step. It is effective at 150 to 300 mg daily, but because it carries hepatotoxicity risk and is a potent enzyme inducer, transaminases warrant monitoring during therapy, and concomitant medications should be reviewed for interactions.^1,2,4

Subsequent rungs include opioid antagonists such as naltrexone, started low and uptitrated to limit withdrawal-like reactions, and the selective serotonin reuptake inhibitor sertraline at 50 to 100 mg daily, with attention to hepatic metabolism in patients with significant impairment.^1,2,5

Newer to the algorithm, the IBAT inhibitor class is now FDA-approved, with linerixibat approved in 2026 specifically for cholestatic pruritus in PBC. By blocking ileal bile acid reabsorption, it increases fecal bile acid elimination. Diarrhea is the predominant, dose-related adverse effect of this class and the main consideration in counseling and tolerability monitoring.^1,6,7

How disease-modifying agents shape itch

Second-line, disease-modifying therapy selection also influences pruritus. Among PPAR agonists, the selective PPAR-delta agonist seladelpar significantly reduced pruritus versus placebo in patients with moderate-to-severe itch at baseline.⁸

The dual PPAR-alpha and -delta agonist elafibranor did not significantly change the primary itch measure versus placebo, though it did not worsen pruritus. The pan-PPAR agonist bezafibrate improved pruritus alongside its biochemical benefit in UDCA-inadequate responders.^9,10

Historically, the farnesoid X receptor (FXR) agonist obeticholic acid worsened pruritus in a dose-dependent fashion; that agent was withdrawn from the US market in late 2025 and is no longer an available option. A 2025 comparative review frames selection as individualized, weighing symptom burden alongside disease stage, comorbidities, and safety.^1,2,11

Eliciting and tracking the burden

Because itch is underreported, structured assessment at diagnosis and each follow-up is essential. A simple numeric rating or visual analog scale quantifies severity and tracks response over time.^1,2

Equally important is probing the downstream burden: Pruritus follows a circadian rhythm that worsens at night, and itch severity correlates strongly with sleep disturbance, so improvement in one tends to track with the other. Asking about sleep loss, daytime exhaustion, and social and emotional impact surfaces a burden that biochemistry will not reveal and informs how aggressively to escalate the symptom-directed ladder.^1,12